Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 27.00
Bid: 26.00
Ask: 28.00
Change: -1.10 (-4.07%)
Spread: 2.00 (7.692%)
Open: 27.00
High: 25.90
Low: 25.90
Prev. Close: 27.00
IKA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on fuel cell catalyst patent in Europe

13 Aug 2015 07:00

RNS Number : 9123V
Ilika plc
13 August 2015
 



13 August 2015

Ilika plc

("Ilika" or the "Company")

 

Update on fuel cell catalyst patent in Europe

 

Ilika (AIM: IKA), the accelerated materials innovation company, announces that the European Patent Office (EPO) has upheld Ilika's opposition to a fuel cell catalyst patent from Brookhaven Science Associates (BSA).

 

Certain claims of a granted European patent from Brookhaven Science Associates (BSA) might have impacted upon Ilika's freedom to operate its own granted European patent. BSA manages Brookhaven National Laboratory (BNL) on behalf of the United States Department of Energy (US DOE). BNL is a US national laboratory located in Upton, New York, on Long Island, primarily funded by the Office of Science of the US DOE.

 

Ilika had therefore filed an Opposition against the BSA patent in February 2013, and oral proceedings took place before the Opposition Division on 17th March 2015 at the European Patent Office (EPO) in Rijswijk, Netherlands. As a result of these proceedings, the BSA European patent was revoked. The EPO issued a notice on 8th August 2015 that the opposition proceedings were now terminated with revocation of the patent as the time limit had expired for filing an appeal against the decision to revoke the patent.

 

Ilika's patents underpin the product development work, which was supported by the Carbon Trust through the £150,000 equity investment Ilika announced in September 2012. The Carbon Trust invested in Ilika through its Polymer Fuel Cells Challenge programme to support the commercialization of Ilika's high performing electro-catalysts for use in fuel cell vehicles. As part of the Carbon Trust's technical and commercial evaluation of the technology, Ilika submitted performance data for assessment by independent experts demonstrating the performance and stability of the catalyst. The performance data was generated in industry standard tests of membrane electrode assemblies (MEA's) carried out at an independent fuel cell testing facility.

 

In December 2013, Ilika announced it had submitted positive cell performance data along with material samples for evaluation to three global OEM's. Initial trials were carried out by these OEM's in 2014 and Ilika continues to support evaluation trials by these three and other OEM's. The adoption rate of fuel cell technology has been historically difficult to predict and at present there is only a limited number of vehicles powered by fuel cells on the UK market. However, the first production Toyota Mirai models landed in Europe this week ahead of the official launch in September. The limited number of cars available in Britain is already sold out. The launch of this vehicle signals an increased focus by OEM's on cost-reduction of fuel cell technology with a view to enabling the mass market.

 

Commenting on this latest development, Graeme Purdy, Ilika CEO, said: "Ilika invests significantly in creating valuable intellectual property to underpin the growth of its business. Potentially competitive filings are monitored very closely and are challenged where appropriate. We welcome this development as we now enjoy freedom to operate our European patent in addition to our United States patent where there had never been such issues because of the different claims structures between the granted US patents of both BSA and Ilika. This positive outcome supports Ilika's commercialisation activities with interested OEM's."

 

 

  

 

 

For more information contact:

 

Ilika plc

www.ilika.com

Graeme Purdy, Chief Executive

Tel: 023 8011 1400

Steve Boydell, Finance Director

 

 

 

Numis Securities Limited

Tel: 020 7260 1000

Oliver Cardigan/ Adrian Trimmings /

 

James Black

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 / ilika@walbrookpr.com

Lianne Cawthorne (Media Enquiries)

Mob: 07584 391 303

Paul Cornelius (Investor Enquiries)

Mob: 07827 879460

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLFFFFTLIFLIE
Date   Source Headline
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20224:40 pmRNSSecond Price Monitoring Extn
16th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20221:29 pmEQSIlika 'well positioned' to deliver battery product combination
17th Nov 20224:40 pmRNSSecond Price Monitoring Extn
17th Nov 20224:35 pmRNSPrice Monitoring Extension
17th Nov 20229:05 amRNSSecond Price Monitoring Extn
17th Nov 20229:00 amRNSPrice Monitoring Extension
17th Nov 20227:01 amRNSAppointment of Chief Financial Officer
17th Nov 20227:00 amRNSTrading Update, Notice of Results & Presentations
22nd Sep 202212:45 pmRNSExercise of Options, PDMR Shareholding and TVR
20th Sep 20224:47 pmRNSResult of AGM
7th Sep 202210:00 amRNSGoliath Scale-up Update
18th Aug 20227:00 amRNSPosting of Annual Report and Notice of AGM
1st Aug 20229:05 amRNSSecond Price Monitoring Extn
1st Aug 20229:00 amRNSPrice Monitoring Extension
25th Jul 20223:30 pmRNSHolding(s) in Company
20th Jul 20222:05 pmRNSSecond Price Monitoring Extn
20th Jul 20222:00 pmRNSPrice Monitoring Extension
14th Jul 20227:00 amRNSExercise of Options and Total Voting Rights
13th Jul 20224:41 pmRNSSecond Price Monitoring Extn
13th Jul 20224:36 pmRNSPrice Monitoring Extension
13th Jul 20227:00 amRNSFinal Results
20th Jun 20227:00 amRNSGoliath Scale-up Update
11th May 20227:00 amRNSTrading Update & Notice of Results
4th May 20227:00 amRNSGoliath Scale-up Update
21st Mar 202211:45 amRNSDirector/PDMR Shareholding
15th Mar 202212:34 pmRNSDirector/PDMR Shareholding
25th Feb 20227:00 amRNSDirectorate Change
24th Feb 20222:01 pmRNSPrice Monitoring Extension
8th Feb 20227:00 amRNSAward of Share Options
7th Feb 202211:01 amRNSPrice Monitoring Extension
20th Jan 20227:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSFirst Stereax Manufacturing Facility Opened
23rd Nov 20215:11 pmRNSHolding(s) in Company
19th Nov 20217:00 amRNSTrading Update & Notice of Half-year Results
10th Nov 20217:00 amRNSCapital Markets Day
22nd Sep 20213:30 pmRNSResult of AGM and Award of Bonus Share Options
10th Sep 20217:00 amRNSCommencement of trading on OTCQX Best Market in US
7th Sep 20217:00 amRNSSenior Appointments and Change of Director
24th Aug 20217:00 amRNSStereax Manufacturing Update
20th Aug 20217:00 amRNSNotice of AGM & Posting of Annual Report
5th Aug 20219:16 amRNSExercise of Options and Total Voting Rights
30th Jul 20214:32 pmRNSHolding(s) in Company
30th Jul 20219:54 amRNSDirector/PDMR Shareholding
29th Jul 20219:00 amRNSExercise of Options and Total Voting Rights
28th Jul 20211:14 pmRNSResults of GM, Open Offer and Total Voting Rights
12th Jul 202112:30 pmRNSPosting of Circular
9th Jul 20214:07 pmRNSResult of Placing and Retail Offer
9th Jul 20217:01 amRNSRetail Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.